

# 1 HLA-A\*01:01 allele vanishing in COVID-19 2 patients population associated with non- 3 structural epitope abundance in CD8<sup>+</sup> T- 4 cell repertoire

5  
6 Maxim Shkurnikov<sup>1\*</sup>, Stepan Nersisyan<sup>1,2,3,4</sup>, Darya Averinskaya<sup>1</sup>, Milena Chekova<sup>1</sup>,  
7 Fedor Polyakov<sup>1</sup>, Aleksei Titov<sup>5</sup>, Dmitriy Doroshenko<sup>6</sup>, Valery Vechorko<sup>6</sup>, Alexander  
8 Tonevitsky<sup>1,2\*</sup>

9  
10 <sup>1</sup>Faculty of Biology and Biotechnology, HSE University, Moscow, Russia

11 <sup>2</sup>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences,  
12 Moscow, Russia

13 <sup>3</sup>Institute of Molecular Biology, The National Academy of Sciences of the Republic of Armenia,  
14 Yerevan, Armenia

15 <sup>4</sup>Armenian Bioinformatics Institute (ABI), Yerevan, Armenia

16 <sup>5</sup>National Research Center for Hematology, Moscow, Russia

17 <sup>6</sup>O.M. Filatov City Clinical Hospital, Moscow, Russia

18

19 \*Correspondence: [mshkurnikov@hse.ru](mailto:mshkurnikov@hse.ru), [atonevitsky@hse.ru](mailto:atonevitsky@hse.ru)

20

## 21 Abstract

22

23 In mid-2021, the SARS-CoV-2 Delta variant caused the third wave of the COVID-19 pandemic  
24 in several countries worldwide. The pivotal studies were aimed at studying changes in the  
25 efficiency of neutralizing antibodies to the spike protein. However, much less attention was  
26 paid to the T-cell response and the presentation of virus peptides by MHC-I molecules. In this  
27 study, we compared the features of the HLA-I genotype in symptomatic patients with COVID-  
28 19 in the first and third waves of the pandemic. As a result, we could identify the vanishing of  
29 carriers of the HLA-A\*01:01 allele in the third wave and demonstrate the unique properties  
30 of this allele. Thus, HLA-A\*01:01-binding immunoprevalent epitopes are mostly derived from  
31 ORF1ab. A set of epitopes from ORF1ab was tested, and their high immunogenicity was  
32 confirmed. Moreover, analysis of the results of single-cell phenotyping of T-cells in recovered  
33 patients showed that the predominant phenotype in HLA-A\*01:01 carriers is central memory  
34 T-cells. The predominance of T-lymphocytes of this phenotype may contribute to forming  
35 long-term T-cell immunity in carriers of this allele. Our results can be the basis for highly  
36 effective vaccines based on ORF1ab peptides.

## 37 Introduction

38

39 The Delta variant of SARS-CoV-2 caused the third wave of the COVID-19 pandemic in mid-  
40 2021 in many countries, including Russia (1). The surge in incidence was associated with the  
41 high transmissibility of this strain compared to the alpha variant (2). The increase in  
42 transmissibility mainly was due to the rise in the number of viral particles exhaled at the peak  
43 of infection by an infected person (up to 6 times compared to the Alpha variant) (3). Aside  
44 from the increased risk of hospitalization, the Delta variant also increases the risk of death in  
45 unvaccinated COVID-19 patients (4).

46

47 In the Delta variant, 18 protein level mutations significantly changed the course of the disease  
48 (5). Five were located in the Spike protein and significantly decreased the effectiveness of  
49 humoral immunity formed either naturally (recovered patients) or after vaccination (6). In  
50 addition, one of these mutations (D614G) increased the affinity of the receptor-binding  
51 domain (RBD) of the Spike protein to the ACE2 receptor (7). Finally, it should be noted that  
52 the rate of virus replication has also changed: the Delta variant replicates two times slower  
53 than the Alpha variant in the first 8 hours after infection *in vitro* (8). This circumstance is  
54 crucial since the non-structural protein ORF8 produced by SARS-CoV-2 can directly interact  
55 with major histocompatibility complex class I (MHC-I) molecules and suppress their  
56 maturation. As a result, the export of MHC-I molecules to an infected cell's surface almost  
57 wholly stops after 18 hours of ORF8 expression (9).

58

59 MHC-I molecules are one of the key mediators of the first steps of a specific immune response  
60 to COVID-19. Right after entering a cell, SARS-CoV-2 induces the translation of its proteins.  
61 Some of these proteins enter the proteasomes of the infected cell, become cleaved to short  
62 peptides (8–12 amino acid residues), and bind to MHC-I molecules. After binding, the complex  
63 consisting of the MHC-I molecule and the peptide is transferred to the infected cell's surface,  
64 where it can interact with the T-cell receptor (TCR) of CD8<sup>+</sup> naïve, central memory or the  
65 effector memory T-cell subpopulations. In response to the interaction, the CD8<sup>+</sup> T-lymphocyte  
66 destroys the infected cell using perforins and serine proteases (10). The crucial role of long-  
67 term CD8<sup>+</sup> T-cell activation in the immune response to SARS-CoV-2 has been recently studied  
68 in a cohort of patients with different severity of disease (11,12).

69

70 There are three main types of MHC-I molecules encoded by HLA-A, HLA-B, and HLA-C (Human  
71 Leukocyte Antigens) genes. Each gene is presented in two variants (alleles) inherited from  
72 parents. There exist dozens of HLA alleles, and every allele encodes an MHC-I molecule with  
73 an individual ability to bind various self- and non-self-antigens (13). Individual combinations  
74 of HLA class I alleles essentially associated with the severity of multiple infectious diseases,  
75 including malaria (14), tuberculosis (15), HIV (16), and viral hepatitis (13). Previously we have  
76 demonstrated the important role of MHC-I peptide presentation in the development of a  
77 specific immune response to the Wuhan-Hu-1 variant (GISAID accession EPI\_ISL\_402125)  
78 (17).

79

80 For over two years of the COVID-19 pandemic, the scientific community accumulated a  
81 significant amount of information on the actual epitopes of various SARS-CoV-2 variants (18),  
82 features of the formation of T-cell memory (19), trends in the frequency of mutations in the  
83 virus (20). However, the associations of the HLA genotypes and the course of COVID-19 were

84 mainly analyzed according to data related to the first wave of the pandemic and the initial  
85 virus variant (21–24). Moreover, in studies of the associations between the severity of COVID-  
86 19 and HLA-I genotypes, the age of the recovered patients was practically not considered. It  
87 should be noted that age is a significant factor in the immune response to COVID-19 (25–27).  
88 In particular, it has been shown that in people over 60 years of age, telomere lengths of naïve  
89 T-lymphocytes decrease significantly, which leads to an almost 10-fold drop in their ability to  
90 divide upon activation (28). Also, the T-cell receptor (TCR) repertoire is reduced in older  
91 people (29).

92

93 Previously, in a cohort of the first wave of COVID-19 patients, we showed that the low number  
94 of peptides presented by an individual’s HLA-I genotype significantly correlates with COVID-  
95 19 severity only in patients under the age of 60 (17). In this study, we compared the features  
96 of the HLA-I genotypes of COVID-19 patients under 60 between the first and the third waves.  
97 In addition, we assessed the influence of mutations in the SARS-CoV-2 variants on the  
98 immunogenic epitopes of CD8<sup>+</sup> T-lymphocytes.

99

## 100 Materials and methods

101

### 102 Design and Participants

103

104 Three groups of patients were enrolled in the study. First, the control group of 428 volunteers  
105 was established using electronic HLA genotype records of the Federal Register of Bone  
106 Marrow Donors (Pirogov Russian National Research Medical University) (17). The group of  
107 147 patients of the first wave of COVID-19 was formed from May to August 2020 (Wave 1  
108 group). Out of them, the subset of 28 COVID-19 convalescent donors of the first wave was  
109 enrolled in a prospective trial (CPS group). Finally, the group of patients of the third wave was  
110 formed from June to July 2021 (Wave 3 group). 219 COVID-19 patients in Wave 3 group  
111 enrolled in O.M. Filatov City Clinical Hospital, (Moscow, Russia).

112

113 All patients had at least one positive test result for SARS-CoV-2 by reverse transcription PCR  
114 (RT-qPCR) from nasopharyngeal swabs or bronchoalveolar lavage. Patients with pathologies  
115 that led to greater morbidity or who had additional immunosuppression (patients with  
116 diabetes, HIV, active cancer in treatment with chemotherapy, immunodeficiency,  
117 autoimmune diseases with immunosuppressants, and transplants) were not included in the  
118 study. The medical practitioner collected blood (2 ml) in ethylenediaminetetraacetic acid  
119 (EDTA) tube for HLA genotyping.

120

121 The severity of the disease was defined according to the classification scheme used by the US  
122 National Institutes of Health (from [www.covid19treatmentguidelines.nih.gov](http://www.covid19treatmentguidelines.nih.gov)): asymptomatic  
123 (lack of symptoms), mild severity (fever, cough, muscle pain, but without respiratory difficulty  
124 or abnormal chest imaging) and moderate/severe (lower respiratory disease at CT scan or  
125 clinical assessment, oxygen saturation (SaO<sub>2</sub>) > 93% on room air, but lung infiltrates less than  
126 50%).

127

128 The study protocol was reviewed and approved by the Local Ethics Committee at the Pirogov  
129 Russian National Research Medical University (Meeting No. 194 of March 16, 2020, Protocol

130 No. 2020/07), by the Local Ethics Committee at O.M. Filatov City Clinical Hospital (Protocol  
131 No. 237 of June 25, 2021), and by the National Research Center for Hematology ethical  
132 committee (N 150, 02.07.2020); the study was conducted in accordance with the Declaration  
133 of Helsinki.

134

### 135 [Human Leukocyte Antigen Class I Genotyping With Targeted Next-Generation](#) 136 [Sequencing](#)

137

138 Genomic DNA was isolated from the frozen collected anticoagulated whole blood samples  
139 using the QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany). HLA genotyping was  
140 performed with the HLA-Expert kit (DNA Technology LLC, Russia) by amplifying exons 2 and 3  
141 of the HLA-A/B/C genes and exon 2 of the HLA-DRB1/3/4/5/DQB1/DPB1 genes. Prepared  
142 libraries were run on Illumina MiSeq sequencer using a standard flow-cell with 2x250 paired-  
143 end sequencing. Reads were analyzed using HLA-Expert Software (DNA-Technology LLC,  
144 Russia) and the IPD-IMGT/HLA database 3.41.0 (30).

145

146 HLA-genotyping of convalescent donors was performed using the One Lambda ALLType kit  
147 (Thermo Fisher Scientific, USA), which uses multiplex PCR to amplify full HLA-A/B/C gene  
148 sequences, and from exon 2 to the 30 UTR of the HLA525 DRB1/3/4/5/DQB1 genes as  
149 described previously (11). Prepared libraries were run on Illumina MiSeq sequencer using a  
150 standard flow-cell with 2x150 paired-end sequencing. Reads were analyzed using One  
151 Lambda HLA TypeStream Visual Software (TSV), version 2.0.0.27232, and the IPD IMGT/HLA  
152 database 3.39.0.0 (30). Processed genotype data are available in Supplementary Table S1.

153

### 154 [Peripheral blood mononuclear cell \(PBMC\) isolation](#)

155

156 30 mL of venous blood from CPS group donors was collected into EDTA tubes (Sarstedt) and  
157 subjected to Ficoll (Paneco) density gradient centrifugation (400 x g, 30 min). Isolated PBMCs  
158 were washed with PBS containing 2 mM EDTA and used for assays or frozen in fetal bovine  
159 serum containing 7% DMSO.

160

### 161 [T-cell expansion](#)

162

163 Full details of the T-cell expansion are provided in the manuscript (11). Briefly, PBMCs  
164 sampled from COVID-19 convalescents were expanded for 12 days with the pre-selected 94  
165 SARS-CoV-2 peptides (final concentration of each = 10  $\mu$ M). On days 10 and 11, an aliquot of  
166 cell suspension was used for anti-IFN- $\gamma$  ELISA aiming at the identification of responses to  
167 individual peptides.

168

### 169 [Cell stimulation with individual peptides](#)

170

171 After 10 days of expansion, an aliquot of cell culture was washed twice in 1.5 mL of PBS and  
172 was then transferred to AIM-V medium (Thermo Fisher Scientific), plated at  $1 \times 10^5$  cells per  
173 well in 96-well plates, and incubated overnight (12–16 hours) with the smaller pools of  
174 peptides, spanning the composition of the initial peptide set. The following day the culture  
175 medium was collected and tested for IFN- $\gamma$  as described below. If the cells reacted positively

176 to one or several pools we sampled an aliquot of cell culture again on days 11–12, and  
177 stimulated it as described above individually with each peptide (2  $\mu$ M) from those peptide  
178 pools. Only peptides predicted to bind to each individual’s HLA were tested.

179

#### 180 [Anti-IFN- \$\gamma\$ ELISA](#)

181

182 Culture 96-well plates with cells, incubated with peptide pools or individual peptides were  
183 centrifuged for 3 minutes at 700g, and 100  $\mu$ L of the medium was transferred to the ELISA  
184 plates and the detection of IFN- $\gamma$  was performed (11). OD was measured at 450 nm on a  
185 MultiScan FC (Thermo Fisher Scientific) instrument (OD450).

186

187 Test wells (medium from cells, incubated with peptides) were compared with negative control  
188 wells (cells incubated with the solvent for peptides). Test wells with the ratio  
189 OD450\_test\_well/OD450\_negative control  $\geq$  1.25 and the difference OD450\_test\_well –  
190 OD450\_negative control  $\geq$  0.08 were considered positive. Peptides with a ratio between 1.25  
191 and 1.5 were tested again up to 3 times as biological replicates to ensure the accuracy of their  
192 response, and peptides with 2 or 3 positive results were considered positive.

193

#### 194 [Peptides](#)

195

196 Peptides (at least 95% purity) were synthesized either by Peptide 2.0 Inc. or by the Shemyakin-  
197 Ovchinnikov Institute of Bioorganic Chemistry RAS.

198

#### 199 [Assessing immunoprevalent epitopes for HLA-A\\*01:01 and HLA-A\\*02:01 and mutations 200 in VOC](#)

201

202 To assess the immunoprevalent epitopes of HLA-A\*01:01 and HLA-A\*02:01, we queried IEDB  
203 (18) for epitopes with positive MHC binding and positive T-cell assays using “Severe acute  
204 respiratory syndrome-related coronavirus” as “Organism” on May 17, 2022. Epitopes with  
205 more than 50% response rate for the respective allele carriers were considered  
206 immunoprevalent. Mutation analysis was performed using data extracted from T-cell COVID-  
207 19 Atlas (20) (accessed May 30, 2022) and included 16 VOC strains.

208

#### 209 [Phenotype analysis of CD8<sup>+</sup> T-lymphocytes of convalescent HLA-A\\*01:01 and HLA- 210 A\\*02:01 allele carriers](#)

211

212 The data were obtained from supplementary materials of Francis et al. (19). The experiment  
213 conducted by the authors consisted in performing single-cell RNA sequencing (scRNA-seq) of  
214 T-cells bound to DNA-barcoded peptide-HLA tetramers. This approach allowed us to extract  
215 information on both TCR sequences and their specific HLA-epitope pairs. Francis with  
216 coauthors used a comprehensive library of SARS-CoV-2 epitopes and epitopes emerging from  
217 SARS-CoV-1, cytomegalovirus, Epstein–Barr virus, and influenza. For the analysis of the  
218 distribution of epitopes across the SARS-CoV-2 genome, the data file S3 was used. It includes  
219 the list of SARS-CoV-2 reactive clonotypes with their specific epitopes and their antigen  
220 source. In addition, the list of SARS-CoV-2 epitopes was extracted, and duplicate entries were  
221 removed.

222

223 The data file S7 was used for the analysis of the T-cell phenotypes. It comprises the  
224 information about the phenotypes of T-cells reacting to particular epitopes. The phenotypes  
225 of T-cells were computationally assigned by the authors based on the analysis of differentially  
226 expressed genes. The authors note that they identified several distinct cell clusters, but  
227 except for naïve cells, central memory, and fully activated cytotoxic effectors, all other  
228 clusters had mixed properties, making it impossible to determine their phenotypes univocally.  
229 Therefore, we decided to take only the definitely determined cell phenotypes into our  
230 analysis: naïve cells, central memory, and fully activated cytotoxic effector cells.

231

### 232 [Bioinformatics analysis of HLA/peptide interactions](#)

233

234 Protein sequences of SARS-CoV-2 variants were obtained from GISAID portal (Elbe &  
235 Buckland-Merrett, 2017): EPI\_ISL\_402125 (Wuhan), EPI\_ISL\_1663516 (Delta, B.1.617.2),  
236 EPI\_ISL\_6699752 (Omicron BA.1, B.1.1.529), EPI\_ISL\_9884589 (Omicron BA.2, B.1.1.529),  
237 EPI\_ISL\_9854919 (Omicron BA.3, B.1.1.529), EPI\_ISL\_11873073 (Omicron BA.4, B.1.1.529).  
238 T-CoV pipeline was executed to analyze HLA/peptide interactions (5,20). In the pipeline's  
239 core, binding affinities of all viral peptides and 169 frequent HLA class I molecules were  
240 predicted using NetMHCpan 4.1 (31).

241

### 242 [Statistical Analysis](#)

243 Allele frequencies in considered cohorts were estimated by dividing the number of  
244 occurrences of a given allele in individuals by the doubled total number of individuals (i.e.,  
245 identical alleles of homozygous individuals were counted as two occurrences). The following  
246 functions from the stats library in R were used to conduct statistical testing: `fisher.test` for  
247 Fisher's exact test, `wilcox.test` for Mann-Whitney U test. In addition, the Benjamini-Hochberg  
248 procedure was used to perform multiple testing corrections. Plots were constructed with  
249 `ggpubr` and `pheatmap` libraries.

250

251



## 252 Results

253

### 254 Distribution of HLA Class I Alleles in the cohorts of patients of the first and the third 255 waves of COVID-19

256

257 We performed HLA class I genotyping of 147 patients who tested positive for COVID-19 during  
258 the first wave of COVID-19 in Moscow (from May to August 2020, Wave 1 group). Also, 219  
259 COVID-19 patients were genotyped from June to July 2021 (Wave 3 group). The demographic  
260 and clinical data of these groups are summarized in Table 1. We did not find significant  
261 differences in the age of patients in the comparison groups and the gender ratio in the groups.  
262 The fraction of vaccinated patients (two doses of Sputnik V vaccine) in the Wave 3 group was  
263 insignificant and equal to 8.7%, slightly lower than the citywide vaccination rate for June 2021  
264 – 15% (32). There was a significant increase in the proportion of patients with obstructive  
265 pulmonary disease (Fisher's exact test  $p = 0.01$ ), obesity (Fisher's exact test  $p = 0.01$ , OR =  
266 3.8), hypertension (Fisher's exact test  $p = 0.003$ , OR = 2.4) in the third wave of COVID-19. We  
267 also assessed the contribution of comorbidities to the risk of death from COVID-19.  
268 Interestingly, heart disease hypertension (Fisher's exact test  $p = 5.2e-5$ , OR = 13) and  
269 hypertension (Fisher's exact test  $p = 0.045$ , OR = 3.5) were significant death risk factors in the  
270 first wave. At the same time, no similar effects were observed for the third wave patients  
271 (Supplementary Table S2).

272

273

274 **Table 1. Characteristics of participants by groups.**

	Wave 1	Wave 3	p-value
<b>n</b>	147	219	
<b>Age</b>	43.4 +/- 11	42.9 +/- 5.2	0,4
<b>Sex</b>			
male	73 (49.7%)	123 (56.2%)	0,24, OR = 0.77
female	74 (50.3%)	96 (43.8%)	
<b>Vaccination</b>	0	19 (8.7%)	4.9e-05
<b>Severity</b>			
mild/moderate	120 (81.6%)	192 (87.7%)	0.13, OR = 0.63
severe	27 (18.4%)	27 (12.3%)	
<b>Outcome</b>			
recovered	127 (86.4%)	197 (90%)	0.32, OR = 0.71
deceased	20 (13.6%)	22 (10%)	
<b>ICU</b>	28 (19%)	51 (23.3%)	0.36, OR = 1.3
<b>Oxygen support</b>			
non	98 (66.7%)	140 (63.9%)	
low flow nasal oxygen supplementation	24 (16.3%)	38 (17.4%)	
prone position	0	11 (5%)	8.8e-05
high-flow oxygen therapy	16 (10.9%)	4 (1.8%)	
mechanical ventilation	9 (6.1%)	26 (11.9%)	
<b>Obstructive pulmonary disease</b>	0	9 (4.1%)	0.01, OR = inf
<b>Obesity</b>	4 (2.7%)	21 (9.6%)	0.01, OR = 3.8
<b>Heart diseases</b>	20 (9.1%)	14 (9.5%)	1, OR = 0.95
<b>Hypertension</b>	16 (10.9%)	50 (22.8%)	0.003, OR = 2.4
<b>Neoplasma</b>	3 (2%)	9 (4.1%)	0.4, OR = 2.1

275

276

277 First, we tested whether the frequency of a single allele can differentiate individuals from  
278 three groups: COVID-19 patients of the first wave, COVID-19 patients of the third wave, and

279 the control group. The distribution of major HLA-A, HLA-B, and HLA-C alleles in these three  
280 groups is summarized in Figure 1. Fisher's exact test was used to make formal statistical  
281 comparisons. As a result, we found that for all possible group comparisons, only one allele  
282 out of dozen top alleles had a high odds ratio, which can be considered statistically significant  
283 after multiple testing correction. Specifically, frequency of HLA-A\*01:01 allele decreased from  
284 17.3% in the Wave 1 group to 9.8% in the Wave 3 group (Fisher's exact test adj.p = 0.025, OR  
285 = 0.5). Some of the alleles were differentially enriched if no multiple testing correction was  
286 applied (Supplementary Table S3).

287  
288 We hypothesized that the decrease in the frequency of HLA-A\*01:01 carriers among patients  
289 of the third wave group could be attributed to the characteristics of the T-cell response. To  
290 test this hypothesis, computational methods were used to analyze the interactions between  
291 the HLA-I molecules and the viral peptides, the effects of mutations in variants of concern  
292 (VOC) on these interactions, as well as the results of experimental testing of the  
293 immunogenicity of peptides in patients who recovered from the COVID-19 in the first wave.

294  
295 [Analysis of the binding affinity of SARS-CoV-2 peptides with MHC-I molecules](#)  
296 The nonstructural proteins encoded by ORF1ab gene are translated first (33) and undergo  
297 proteasomal digestion before structural and accessory proteins (including ORF8 which  
298 suppress MHC-I maturation). Given that, we analyzed the ability of MHC-I molecules encoded  
299 by 12 most common alleles in the European population (34) (Figure 2) to bind and present  
300 ORF1ab and non-ORF1ab peptides. The ability of HLA-A\*01:01 to interact with peptides of  
301 both structural and non-structural proteins of the virus was moderate. Namely, it was  
302 predicted to interact with an affinity of less than 50 nM (tight binding peptides) with 28  
303 peptides from ORF1ab and 8 peptides from structural and accessory proteins. Another allele,  
304 HLA-A\*02:01, was the most frequent in the population and had 207 predicted tight binders  
305 from ORF1ab and 56 tight binders from the other proteins. We also compared the ability to  
306 present viral peptides between genotypes that include HLA-A\*01:01 and genotypes which do  
307 not include this allele (Figure S1 A). HLA-I genotypes, which included HLA-A\*01:01, had, on  
308 average, a lower number of high-affinity peptides compared to non-carriers regardless of  
309 wave (Mann-Whitney U test  $p < 0.02$ ).

310  
311 It should be noted that variant AY.122 (1) prevailed in the third wave of COVID-19 in the  
312 Moscow region. One of its characteristic mutations is G8R in the NS8 (ORF8) protein. This  
313 mutation causes a decrease in the affinity of the interaction of peptides NS8<sub>5-13</sub> (FLGIITTV)  
314 and NS8<sub>2-13</sub> (FLVFLGIITTV) with the MHC-I molecule encoded by the most frequent HLA-  
315 A\*02:01 allele for the analyzed population. This mutation is associated with a non-significant  
316 reduction in the number of high-affinity accessory protein epitopes in HLA-A\*01:01 carriers  
317 (Figure S1 B).

318  
319 [Analysis of immunogenic epitopes](#)  
320 Next, we analyzed the immunogenic epitopes of SARS-CoV-2 using the data from the IEDB  
321 portal for HLA-A\*01:01 and HLA-A\*02:01 alleles. At the time of the analysis (May 2022), the  
322 database contained information on the T-cell responses to 365 viral peptides. Two shared  
323 epitopes were found for both alleles: S<sub>136-144</sub> (CNDPFLGVY), M<sub>170-178</sub> (VATSRTLSTY). For the  
324 HLA-A\*01:01 allele, the immunogenicity of 50 ORF1ab peptides and 33 non-ORF1ab peptides  
325 was validated. In entire agreement with computational predictions, the number of epitopes



326 was higher for the HLA-A\*02:01 allele: 139 ORF1ab peptides and 145 non-ORF1ab peptides.  
327 The ratio of peptides from ORF1ab for the HLA-A\*01:01 allele was 1.6 times higher than for  
328 the HLA-A\*02:01 allele (Fisher's Exact Test p-value = 0.08). Among the tested peptides,  
329 immunoprevalent epitopes were identified (i.e., caused a response of T-lymphocytes in at  
330 least 50% of the tested samples). For the HLA-A\*01:01 allele, 10 immunoprevalent epitopes  
331 from ORF1ab and only 3 epitopes not from ORF1ab were identified. For the HLA-A\*02:01  
332 allele, 51 immunoprevalent epitopes from ORF1ab and 59 from non-ORF1ab were identified.  
333 The ratio of immunoprevalent epitopes from ORF1ab for the HLA-A\*01:01 allele was 3.8 times  
334 higher than for the HLA-A\*02:01 allele (Fisher's Exact Test p-value = 0.04).

335

### 336 Validation of ORF1ab epitopes in a subset of convalescent HLA-A\*01:01 and HLA- 337 A\*02:01 carriers

338 To validate the hypothesis that the first wave convalescent HLA-A\*01:01 allele carriers had a  
339 high number of immunogenic epitopes from ORF1ab proteins, we analyzed the T-cell  
340 responses of 28 patients with the history of confirmed COVID-19 during first wave who carried  
341 at least one of the two most common alleles in the European population: HLA-A\*01:01 (13  
342 patients) and HLA-A\*02:01 (15 patients). Individual immunogenicity of 15 validated epitopes  
343 from SARS-CoV-2 ORF1ab (Supplementary Table S4) was tested for each T-cell sample. The  
344 peptides from this panel did not induce a T-cell response in patients who had not previously  
345 had COVID-19 (11). The number of epitopes for HLA-A\*01:01 was 7 for HLA-A\*02:01 – 8.

346

347 Since time from the symptoms onset to the first measurement could affect the strength of  
348 the T-cell response, we compared these times between groups of HLA-A\*01:01 and HLA-  
349 A\*02:01 carriers. For HLA-A\*01:01 carriers, the median time after symptoms onset was 34  
350 days, and for HLA-A\*02:01 carriers, it was 41 days; the differences were insignificant (Figure  
351 3A). At the same time, the true positive rates for these alleles differed significantly for  
352 epitopes from ORF1ab (Figure 3B). Three of the 7 HLA-A\*01:01 epitopes tested were  
353 immunoprevalent (ORF1ab<sub>1637-1646</sub> TTDPSFLGRY, ORF1ab<sub>1636-1646</sub> HTTDPSFLGRY, ORF1ab<sub>1321-  
354 1329</sub> PTDNYITTY), but there were no immunoprevalent epitopes out of 8 tested for HLA-  
355 A\*02:01.

356

### 357 Phenotype analysis of CD8<sup>+</sup> T-lymphocytes of convalescent patients

358 Aside from IEDB and own epitope validation data, we analyzed *ex vivo* scRNA-seq data of  
359 convalescent individuals CD8<sup>+</sup> T-cells activated by single peptides (19). The considered dataset  
360 included the set of phenotyped T-cell clones responding to a comprehensive set of SARS-CoV-  
361 2 derived epitopes associated with four major HLA class I alleles (HLA-A\*01:01, HLA-A\*02:01,  
362 HLA-A\*24:02, and HLA-B\*07:02). First, we examined the distribution of SARS-CoV-2 derived  
363 epitopes which elicited T-cell response according to the genomic region from which they  
364 originated. Concordantly with the results mentioned above, the majority of HLA-A\*01:01  
365 epitopes were from ORF1ab. The same tendency was not observed for the other alleles  
366 (Figure 4A).

367

368 Next, we analyzed the phenotypes of responding T-cell clones (Figure 4B). HLA-A\*01:01-  
369 associated epitopes elicited responses mainly from the Tcm subpopulation. At the same time,  
370 the proportion of Tcm responding cells for other alleles was significantly smaller (Fisher Exact  
371 Test pairwise comparisons of A\*01:01 with A\*02:01, B\*07:02, and A\*24:02 results in p-values  
372 < 0.02). Together with the observation that most of the known HLA-A\*01:01-associated

373 epitopes originated from the conservative ORF1ab region, these results imply that people  
374 bearing HLA-A\*01:01 may have a higher chance of eliciting robust immune response upon  
375 secondary exposure to SARS-CoV-2 due to the pre-existing immune memory.  
376

#### 377 [Analysis of the mutations in the VOC on CD8<sup>+</sup> epitopes](#)

378 Then, we analyzed the changes in the affinity of the interactions of immunoprevalent  
379 epitopes with HLA-A\*01:01 and HLA-A\*02:01 induced by mutations in VOCs, including the  
380 Delta variant. Strikingly, none of the HLA-A\*01:01 immunoprevalent epitopes were affected  
381 by mutations in the current VOCs: Delta G/478K.V1 and Omicron (BA.1 – BA.4). At the same  
382 time, seven HLA-A\*02:01 immunoprevalent epitopes were affected by the mutations. Six  
383 were located in the Spike protein and one in the NS3 protein. All except one mutation led to  
384 the decrease in the affinity of the interaction with HLA-A\*02:01. Specifically, in Omicron BA.1  
385 the S<sub>495-503</sub> YGFQPTNGV peptide had three substitutions (G496S, Q498R, N501Y), which  
386 resulted in an increase in the affinity of its interaction with HLA-A\*02:01 (from 2160 nM to 87  
387 nM). In VOC Omicron BA.1 and BA.3, A67V and HV 69-70 deletion mutations resulted in the  
388 disappearance of the immunoprevalent epitope S<sub>62-70</sub> VTWFHAIHV.  
389

390 In addition, the effect of mutations in the VOCs on the binding affinity of all possible viral  
391 peptides with the 12 abovementioned HLA-I alleles was analyzed (Table 2). HLA-A\*01:01 had  
392 51 high-affinity peptides from ORF1ab and 13 high-affinity peptides from other proteins  
393 (structural and accessory) for the Wuhan-Hu-1 strain. A distinctive feature of this allele was  
394 that it had a relatively high number of high-affinity peptides, although VOC mutations do not  
395 affect them (Figure 5). Of the 64 high-affinity HLA-A\*01:01 peptides, only one peptide  
396 significantly changed the affinity in 16 VOCs analyzed. At the same time, similar to the number  
397 of tight binders allele HLA-A\*24:02 had 27 altered peptides from ORF1ab (Fisher's exact test  
398 p-value = 3e-09, OR = 0.02). It should be noted that the high-affinity peptides from ORF1ab  
399 for all analyzed alleles were less affected by the mutations compared to the rest of the  
400 peptides (Mann-Whitney U test p-value = 4.3e-05).  
401

402 **Table 2. The number of high-affinity peptides mutated in VOCs.**

Allele	Frequency in study population	Total number of new and disappeared non ORF1ab tight binders in all VOC	Total number of new and disappeared ORF1ab tight binders in all VOC	Number of non ORF1ab tight binders in Wuhan-Hu-1	Number of ORF1ab tight binders in Wuhan-Hu-1
HLA-A*02:01	25.44	43	29	96	305
HLA-A*03:01	12.97	36	15	29	100
HLA-C*12:03	12.78	7	1	32	72
HLA-A*01:01	13.1	18	10	13	51
HLA-A*24:02	11.34	9	11	17	46
HLA-B*07:02	9.89	51	19	16	39
HLA-B*08:01	7.24	10	18	12	29
HLA-B*18:01	7.24	10	4	7	25
HLA-C*07:02	11.71	2	2	1	10
HLA-C*06:02	10.96	4	2	1	5
HLA-C*07:01	12.03	0	0	0	0
HLA-C*04:01	12.41	0	1	0	0

403

## 404 Discussion

405

406 We conducted a comparative study of the HLA-I genotypes of symptomatic COVID-19 patients  
 407 of the pandemic's first and third waves. Genotypes of 147 patients (first wave) and 219 (third  
 408 wave) were studied. We found a significant increase in the proportion of patients with  
 409 obstructive pulmonary disease, obesity, and hypertension in the third wave of COVID-19. This  
 410 circumstance may be associated not only with the peculiarities of the Delta variant but also  
 411 with the possible population's fatigue from complying with anti-epidemic measures, which  
 412 led to the infection of risk groups that previously more strictly kept the social distancing  
 413 regime (35).

414

415 We tested whether the frequency of HLA alleles can differentiate individuals from three  
 416 groups: COVID-19 patients of the first wave, COVID-19 patients of the third wave, and the  
 417 control group. We found that for all possible group comparisons, only one allele out of the  
 418 most abundant alleles had a statistically significant odds ratio after multiple testing  
 419 correction. Namely, the frequency of the HLA-A\*01:01 allele in the Wave 3 group fell by half  
 420 relative to the Wave 1 group. Previously, the HLA-A\*01:01 allele was considered a risk allele  
 421 for infection and severe course of COVID-19 in the first wave (17,36–38). At the same time,  
 422 the protective role of this allele against the formation of Severe Bilateral Pneumonia caused  
 423 by COVID-19 was also reported (39).

424

425 We suggested that the decrease in the frequency of HLA-A\*01:01 carriers among patients of  
 426 the third wave could be associated with the characteristics of the previously formed T-cell  
 427 responses. It is known that up to 50% of cases of COVID-19 are asymptomatic (40,41) and lead

428 to the formation of neutralizing antibodies and multispecific T-cells (42). While the efficiency  
429 of neutralizing antibodies decreases for VOCs (43), the formed pool of multispecific T-cells in  
430 most cases can provide an immune response regardless of viral mutations (5).

431  
432 To test this hypothesis, we first analyzed the number of viral peptides interacting with the 12  
433 most common alleles in the European population with bioinformatics methods. HLA-A\*01:01  
434 allele was one of the alleles with a moderate ability to interact with peptides of both structural  
435 and non-structural proteins of the virus. We also found that HLA-A\*01:01 carriers have fewer  
436 predicted high-affinity peptides compared to the non-carriers, regardless of the wave of  
437 COVID-19.

438  
439 Analysis of the confirmed immunogenic epitopes of SARS-CoV-2 according to the IEDB  
440 database showed that 10 immunoprevalent epitopes from ORF1ab and only 3 not from  
441 ORF1ab were identified for HLA-A\*01:01. In turn, there were 51 immunoprevalent epitopes  
442 from ORF1ab and 59 epitopes not from ORF1ab for the HLA-A\*02:01 allele. Thus, the ratio of  
443 immunoprevalent epitopes from ORF1ab for the HLA-A\*01:01 allele was 3.8 times greater  
444 than for the HLA-A\*02:01 allele. We additionally validated these data by analyzing the T-cell  
445 responses of 28 carriers HLA-A\*01:01 and HLA-A\*02:01 alleles. Concordantly with IEDB data,  
446 the true positive rates for ORF1ab epitopes were significantly higher for HLA-A\*01:01  
447 compared to the HLA-A\*02:01. One of the possible explanations for these data may be the  
448 higher proportion of formed central memory CD8<sup>+</sup> T-cells in HLA-A\*01:01 carriers compared  
449 to the A\*02:01, B\*07:02, and A\*24:02 carriers.

450  
451 Moreover, an ORF1ab-derived HLA-A\*01:01-restricted epitope TTDPSFLRGY was shown in  
452 multiple studies to induce exceptionally high frequency of T-cells (magnitude of response) in  
453 comparison to other multiple immunoprevalent epitopes (44–47). Furthermore, it was shown  
454 that the response of PBMCs of HLA-A\*01:01+ convalescents to the epitopes derived from  
455 non-structural proteins was higher than to the structural proteins. This was not observed for  
456 HLA-A\*01:01- convalescents (11). This further suggests high importance of ORF1ab-focused  
457 T-cell response for carriers of HLA-A\*01:01.

458  
459 Not a single immunoprevalent HLA-A\*01:01 epitope significantly changed its presentation  
460 affinity due to mutations in the actual VOCs: Delta G/478K.V1, Omicron (BA.1 – BA. 4). At the  
461 same time, other alleles such as HLA-A\*02:01 were affected by the mutations. Interestingly,  
462 HLA-A\*01:01 was the only allele with a relatively high number of high-affinity peptides  
463 unaffected by the mutations. In agreement with the reports on the lower mutation rate in  
464 ORF1ab (48), high-affinity peptides from ORF1ab for all analyzed alleles were less affected by  
465 mutations compared to the rest of the proteins.

466  
467 This study demonstrates for the first time the possibility of HLA-A\*01:01 allele vanishment  
468 between the cohorts of symptomatic COVID-19 patients from different waves. Furthermore,  
469 the discovered characteristics of peptide presentation by HLA-A\*01:01 could be important  
470 for developing vaccines to induce T-cell responses.

471

## 472 Acknowledgments

473 The research was performed within the framework of the “Creation of Experimental  
474 Laboratories in the Natural Sciences Program” at the HSE University. Funding for open access  
475 charge: Laboratory for Research on Molecular Mechanisms of Longevity, HSE University.  
476

## 477 References



- 478 1. Klink G, Safina K, Nabieva E, Shvyrev N, Garushyants S, Alekseeva E, Komissarov A,  
479 Danilenko D, Pochtovyi A, Divisenko E, et al. The rise and spread of the SARS-CoV-2  
480 AY.122 lineage in Russia. *Virus Evolution* (2022) 8: doi: 10.1093/ve/veac017
- 481 2. Callaway E. Delta coronavirus variant: scientists brace for impact. *Nature* (2021)  
482 595:17–18. doi: 10.1038/d41586-021-01696-3
- 483 3. Earnest R, Uddin R, Matluk N, Renzette N, Turbett SE, Siddle KJ, Loreth C, Adams G,  
484 Tomkins-Tinch CH, Petrone ME, et al. Comparative transmissibility of SARS-CoV-2  
485 variants Delta and Alpha in New England, USA. *Cell Reports Medicine* (2022) 3:100583.  
486 doi: 10.1016/j.xcrm.2022.100583
- 487 4. Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the  
488 delta variant in the USA. *The Lancet Infectious Diseases* (2021) 21:1629–1630. doi:  
489 10.1016/S1473-3099(21)00685-X
- 490 5. Nersisyan S, Zhiyanov A, Zakharova M, Ishina I, Kurbatskaia I, Mamedov A, Galatenko  
491 A, Shkurnikov M, Gabibov A, Tonevitsky A. Alterations in SARS-CoV-2 Omicron and  
492 Delta peptides presentation by HLA molecules. *PeerJ* (2022) 10:e13354. doi:  
493 10.7717/peerj.13354
- 494 6. Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, Mao Q, Xu M, Liang Z. Impact of the Delta  
495 variant on vaccine efficacy and response strategies. *Expert Review of Vaccines* (2021)  
496 20:1201–1209. doi: 10.1080/14760584.2021.1976153
- 497 7. Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, Miyoshi K, Kishigami S, Ueno T, Iwatani  
498 Y, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced  
499 ACE2-binding affinity. *Nature Communications* (2021) 12:848. doi: 10.1038/s41467-  
500 021-21118-2
- 501 8. Shuai H, Chan JF-W, Hu B, Chai Y, Yuen TT-T, Yin F, Huang X, Yoon C, Hu J-C, Liu H, et al.  
502 Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. *Nature*  
503 (2022) 603:693–699. doi: 10.1038/s41586-022-04442-5
- 504 9. Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, Xia B, Ma X, Yang T, Yu F, et al. The ORF8  
505 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-I.  
506 *Proceedings of the National Academy of Sciences* (2021) 118: doi:  
507 10.1073/pnas.2024202118
- 508 10. Wherry EJ, Ahmed R. Memory CD8 T-Cell Differentiation during Viral Infection. *Journal*  
509 *of Virology* (2004) 78:5535–5545. doi: 10.1128/jvi.78.11.5535-5545.2004
- 510 11. Titov A, Shaykhutdinova R, Shcherbakova O v., Serdyuk Y v., Sheetikov SA, Zornikova K  
511 v., Maleeva A v., Khmelevskaya A, Dianov D v., Shakirova NT, et al. Immunogenic  
512 epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-  
513 2. *JCI Insight* (2022) 7: doi: 10.1172/jci.insight.157699
- 514 12. Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R, Kratzer B, Mühl B, Perkmann  
515 T, Trapin D, Trella M, et al. Antibodies in serum of convalescent patients following mild  
516 COVID-19 do not always prevent virus-receptor binding. *Allergy* (2021) 76:878–883.  
517 doi: 10.1111/all.14523
- 518 13. Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O’Gorman M, Beaman K, Cotler  
519 SJ, Hershow R, et al. Ethnic and geographical differences in HLA associations with the  
520 outcome of hepatitis C virus infection. *Virology Journal* (2009) 6: doi: 10.1186/1743-  
521 422X-6-46



- 522 14. Lima-Junior J da C, Pratt-Riccio LR. Major histocompatibility complex and malaria:  
523 Focus on Plasmodium vivax Infection. *Frontiers in Immunology* (2016) 7: doi:  
524 10.3389/fimmu.2016.00013
- 525 15. Mazzaccaro RJ, Gedde M, Jensen ER, van Santen HM, Ploegh HL, Rock KL, Bloom BR.  
526 Major histocompatibility class I presentation of soluble antigen facilitated by  
527 Mycobacterium tuberculosis infection. *Proc Natl Acad Sci U S A* (1996) 93:11786–  
528 11791. doi: 10.1073/pnas.93.21.11786
- 529 16. Goulder PJR, Watkins DI. Impact of MHC class I diversity on immune control of  
530 immunodeficiency virus replication. *Nature Reviews Immunology* (2008) 8:619–630.  
531 doi: 10.1038/nri2357
- 532 17. Shkurnikov M, Nersisyan S, Jankevic T, Galatenko A, Gordeev I, Vechorko V, Tonevitsky  
533 A. Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19.  
534 *Frontiers in Immunology* (2021) 12:641900. doi: 10.3389/fimmu.2021.641900
- 535 18. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A,  
536 Peters B. The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Research*  
537 (2019) 47:D339–D343. doi: 10.1093/nar/gky1006
- 538 19. Francis JM, Leistritz-Edwards D, Dunn A, Tarr C, Lehman J, Dempsey C, Hamel A, Rayon  
539 V, Liu G, Wang Y, et al. Allelic variation in class I HLA determines CD8+ T cell repertoire  
540 shape and cross-reactive memory responses to SARS-CoV-2. *Sci Immunol* (2022)  
541 7:eabk3070. doi: 10.1126/sciimmunol.abk3070
- 542 20. Nersisyan S, Zhiyanov A, Shkurnikov M, Tonevitsky A. T-CoV: a comprehensive portal  
543 of HLA-peptide interactions affected by SARS-CoV-2 mutations. *Nucleic Acids Research*  
544 (2022) 50:D883–D887. doi: 10.1093/nar/gkab701
- 545 21. Tavasolian F, Rashidi M, Hatam GR, Jeddi M, Hosseini AZ, Mosawi SH, Abdollahi E,  
546 Inman RD. HLA, Immune Response, and Susceptibility to COVID-19. *Frontiers in*  
547 *Immunology* (2021) 11: doi: 10.3389/fimmu.2020.601886
- 548 22. Lorente L, Martín MM, Franco A, Barrios Y, Cáceres JJ, Solé-Violán J, Perez A, Marcos y  
549 Ramos JA, Ramos-Gómez L, Ojeda N, et al. HLA genetic polymorphisms and prognosis  
550 of patients with COVID-19. *Medicina Intensiva* (2021) 45:96–103. doi:  
551 10.1016/j.medin.2020.08.004
- 552 23. Langton DJ, Bourke SC, Lie BA, Reiff G, Natu S, Darlay R, Burn J, Echevarria C. The  
553 influence of HLA genotype on the severity of COVID-19 infection. *HLA* (2021) 98:14–22.  
554 doi: 10.1111/tan.14284
- 555 24. Venet F, Gossez M, Bidar F, Bodinier M, Coudereau R, Lukaszewicz A-C, Tardiveau C,  
556 Brengel-Pesce K, Cheynet V, Cazalis M-A, et al. T cell response against SARS-CoV-2  
557 persists after one year in patients surviving severe COVID-19. *eBioMedicine* (2022)  
558 78:103967. doi: 10.1016/j.ebiom.2022.103967
- 559 25. Promislow DEL. A Geroscience Perspective on COVID-19 Mortality. *The Journals of*  
560 *Gerontology: Series A* (2020) 75:e30–e33. doi: 10.1093/gerona/glaa094
- 561 26. McGroder CF, Zhang D, Choudhury MA, Salvatore MM, D’Souza BM, Hoffman EA, Wei  
562 Y, Baldwin MR, Garcia CK. Pulmonary fibrosis 4 months after COVID-19 is associated  
563 with severity of illness and blood leucocyte telomere length. *Thorax* (2021) 76:1242–  
564 1245. doi: 10.1136/thoraxjnl-2021-217031
- 565 27. Sanchez-Vazquez R, Guío-Carrión A, Zapatero-Gaviria A, Martínez P, Blasco MA. Shorter  
566 telomere lengths in patients with severe COVID-19 disease. *Aging* (2021) 13:1–15. doi:  
567 10.18632/aging.202463


- 568 28. Anderson JJ, Susser E, Arbeev KG, Yashin AI, Levy D, Verhulst S, Aviv A. Telomere-length  
569 dependent T-cell clonal expansion: A model linking ageing to COVID-19 T-cell  
570 lymphopenia and mortality. *eBioMedicine* (2022) 78:103978. doi:  
571 10.1016/j.ebiom.2022.103978
- 572 29. Britanova O v., Putintseva E v., Shugay M, Merzlyak EM, Turchaninova MA, Staroverov  
573 DB, Bolotin DA, Lukyanov S, Bogdanova EA, Mamedov IZ, et al. Age-Related Decrease  
574 in TCR Repertoire Diversity Measured with Deep and Normalized Sequence Profiling.  
575 *The Journal of Immunology* (2014) 192:2689–2698. doi: 10.4049/jimmunol.1302064
- 576 30. Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA  
577 Database. *Nucleic Acids Research* (2020) 48:D948–D955. doi: 10.1093/nar/gkz950
- 578 31. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-  
579 4.0: improved predictions of MHC antigen presentation by concurrent motif  
580 deconvolution and integration of MS MHC eluted ligand data. *Nucleic Acids Res* (2020)  
581 48:W449–W454. doi: 10.1093/nar/gkaa379
- 582 32. Boguslavsky D v., Sharova NP, Sharov KS. Public Policy Measures to Increase Anti-SARS-  
583 CoV-2 Vaccination Rate in Russia. *International Journal of Environmental Research and  
584 Public Health* (2022) 19:3387. doi: 10.3390/ijerph19063387
- 585 33. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication:  
586 implications for SARS-CoV-2. *Nature Reviews Microbiology* (2021) 19:155–170. doi:  
587 10.1038/s41579-020-00468-6
- 588 34. Gonzalez-Galarza FF, McCabe A, Santos EJM dos, Jones J, Takeshita L, Ortega-Rivera  
589 ND, Cid-Pavon GM del, Ramsbottom K, Ghattaoraya G, Alfirevic A, et al. Allele  
590 frequency net database (AFND) 2020 update: gold-standard data classification, open  
591 access genotype data and new query tools. *Nucleic Acids Research* (2019) doi:  
592 10.1093/nar/gkz1029
- 593 35. Chan EYY, Kim JH, Kwok K, Huang Z, Hung KKC, Wong ELY, Lee EKP, Wong SYS.  
594 Population Adherence to Infection Control Behaviors during Hong Kong's First and  
595 Third COVID-19 Waves: A Serial Cross-Sectional Study. *International Journal of  
596 Environmental Research and Public Health* (2021) 18:11176. doi:  
597 10.3390/ijerph182111176
- 598 36. Pisanti S, Deelen J, Gallina AM, Caputo M, Citro M, Abate M, Sacchi N, Vecchione C,  
599 Martinelli R. Correlation of the two most frequent HLA haplotypes in the Italian  
600 population to the differential regional incidence of Covid-19. *Journal of Translational  
601 Medicine* (2020) 18: doi: 10.1186/s12967-020-02515-5
- 602 37. Naemi FMA, Al-adwani S, Al-khatibi H, Al-nazawi A. Frequency of HLA alleles among  
603 COVID-19 infected patients: Preliminary data from Saudi Arabia. *Virology* (2021) 560:1–  
604 7. doi: 10.1016/j.virol.2021.04.011
- 605 38. Ishii T. Human Leukocyte Antigen (HLA) Class I Susceptible Alleles Against COVID-19  
606 Increase Both Infection and Severity Rate. *Cureus* (2020) doi: 10.7759/cureus.12239
- 607 39. Suslova TA, Vavilov MN, Belyaeva S v, Evdokimov A v., Stashkevich DS, Galkin A, Kofiadi  
608 IA. Distribution of HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 allele frequencies in patients with  
609 COVID-19 bilateral pneumonia in Russians, living in the Chelyabinsk region (Russia).  
610 *Human Immunology* (2022) 83:547–550. doi: 10.1016/j.humimm.2022.04.009
- 611 40. Alene M, Yismaw L, Assemie MA, Ketema DB, Mengist B, Kassie B, Birhan TY. Magnitude  
612 of asymptomatic COVID-19 cases throughout the course of infection: A systematic  
613 review and meta-analysis. *PLOS ONE* (2021) 16:e0249090. doi:  
614 10.1371/journal.pone.0249090

- 615 41. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the  
616 extent of asymptomatic COVID-19 and its potential for community transmission:  
617 Systematic review and meta-analysis. *Official Journal of the Association of Medical*  
618 *Microbiology and Infectious Disease Canada* (2020) 5:223–234. doi: 10.3138/jammi-  
619 2020-0030
- 620 42. Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, Schmidt NM, Butler  
621 DK, Amin OE, Bailey SNL, et al. Discordant neutralizing antibody and T cell responses in  
622 asymptomatic and mild SARS-CoV-2 infection. *Science Immunology* (2020) 5: doi:  
623 10.1126/sciimmunol.abf3698
- 624 43. Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, Hallett SR,  
625 Pickering S, Charalampous T, et al. Neutralizing antibody activity in convalescent sera  
626 from infection in humans with SARS-CoV-2 and variants of concern. *Nature*  
627 *Microbiology* (2021) 6:1433–1442. doi: 10.1038/s41564-021-00974-0
- 628 44. Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, Carbajo D, Abel B, Newell  
629 EW, Bettinotti MP, et al. SARS-CoV-2–specific CD8+ T cell responses in convalescent  
630 COVID-19 individuals. *Journal of Clinical Investigation* (2021) 131: doi:  
631 10.1172/JCI145476
- 632 45. Saini SK, Hersby DS, Tamhane T, Povlsen HR, Amaya Hernandez SP, Nielsen M, Gang  
633 AO, Hadrup SR. SARS-CoV-2 genome-wide T cell epitope mapping reveals  
634 immunodominance and substantial CD8+ T cell activation in COVID-19 patients. *Sci*  
635 *Immunol* (2021) 6: doi: 10.1126/sciimmunol.abf7550
- 636 46. Gangaev A, Ketelaars SLC, Isaeva OI, Patiwaal S, Dopler A, Hoefakker K, de Biasi S,  
637 Gibellini L, Mussini C, Guaraldi G, et al. Identification and characterization of a SARS-  
638 CoV-2 specific CD8+ T cell response with immunodominant features. *Nat Commun*  
639 (2021) 12:2593. doi: 10.1038/s41467-021-22811-y
- 640 47. Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, Zahid HJ,  
641 Kaplan IM, Dines JN, Noakes MT, et al. Magnitude and Dynamics of the T-Cell Response  
642 to SARS-CoV-2 Infection at Both Individual and Population Levels. *medRxiv* (2020) doi:  
643 10.1101/2020.07.31.20165647
- 644 48. Vilar S, Isom DG. One Year of SARS-CoV-2: How Much Has the Virus Changed? *Biology*  
645 *(Basel)* (2021) 10:91. doi: 10.3390/biology10020091  
646










Population	Wave 1	Wave 3	
24.4	25.5	28.4	HLA-A*02:01
13.3	17.3	9.2	HLA-A*01:01
13.3	11.6	13.8	HLA-A*03:01
12.6	11.9	12.0	HLA-C*07:01
12.5	13.5	10.8	HLA-C*04:01
12.1	7.5	14.0	HLA-C*07:02
12.0	13.2	14.6	HLA-C*12:03
11.8	9.4	11.6	HLA-A*24:02
11.2	13.2	9.2	HLA-C*06:02
10.9	6.3	11.0	HLA-B*07:02
7.0	7.9	6.6	HLA-B*08:01
7.0	4.1	6.8	HLA-B*44:02
6.9	7.5	9.0	HLA-B*18:01
6.3	4.7	5.0	HLA-B*35:01
5.8	4.4	6.0	HLA-C*02:02
5.5	7.2	5.0	HLA-B*13:02
5.1	3.5	7.0	HLA-A*26:01
5.1	7.9	5.8	HLA-B*51:01
5.1	6.9	5.6	HLA-C*03:04
5.0	5.7	6.6	HLA-A*11:01
4.8	4.4	6.4	HLA-B*38:01
4.8	2.5	4.0	HLA-C*05:01
4.2	6.3	7.4	HLA-A*25:01
3.7	3.1	2.8	HLA-C*03:03
3.6	4.1	3.8	HLA-B*15:01
3.4	5.7	4.4	HLA-C*01:02
3.3	1.3	1.4	HLA-A*68:01
3.2	2.8	3.2	HLA-A*32:01
3.0	3.8	3.0	HLA-B*27:05
3.0	5.7	2.6	HLA-B*40:01
2.7	3.5	2.4	HLA-A*23:01
2.7	4.4	3.0	HLA-B*44:03
2.7	1.3	1.8	HLA-C*17:01
2.6	2.5	1.8	HLA-C*08:02
2.5	1.9	2.6	HLA-B*40:02
2.3	1.6	2.6	HLA-B*35:03
2.3	3.5	1.0	HLA-C*15:02
2.2	2.8	1.2	HLA-A*30:01
2.2	2.2	3.0	HLA-C*12:02
2.1	2.8	3.2	HLA-B*52:01








**A****B**



1 Figures


2



3


4

5 **Figure 1. Distribution of HLA-A, HLA-B, and HLA-C allele frequencies in the groups of**  
 6 **COVID-19 patients and the control group. Alleles with frequency over 5% in at least one of**  
 7 **three considered groups are presented.**




8  
9  
10  
11  
12  
13

**Figure 2. The number of virus peptides interacting with the most frequent alleles with an affinity of no more than 50 nM.**



14  
15  
16  
17  
18  
19  
20


**Figure 3. Validation of ORF1ab epitopes immunogenicity in a subset of convalescent HLA-A\*01:01 and HLA-A\*02:01 carriers.** (A) Distribution of days between symptoms onset and blood sampling in the comparison groups. (B) True positive rates for the ORF1ab epitope set in the comparison groups.



21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33


**Figure 4. Phenotype analysis of CD8+ T-lymphocytes of convalescent patients.** (A) The distribution of SARS-CoV-2 derived immunogenic epitopes according to their genomic origin. Epitopes associated with the HLA-A\*01:01 allele tend to originate mainly from the conservative ORF1ab region, suggesting a prevalence of memory T-cells among the responding T-cells during the second encounter with SARS-CoV-2. (B) The ratio of responding T-cell phenotypes to the comprehensive set of SARS-CoV-2 derived epitopes. Tcm stands for T central memory subpopulation, and CTE stands for cytotoxic T effector cells. Epitopes associated with the HLA-A\*01:01 allele elicit a more robust Tcm response compared with other alleles (pairwise Fisher exact test values: 5.423e-05 for A\*01:01 against A\*02:02 comparison, 0.0178 for A\*01:01 against B\*07:02 comparison, 6.196e-05 for A\*01:01 against A\*24:02 comparison).





34  
 35 **Figure 5. Effect of mutations in the VOC on the number of tight binders for alleles HLA-**  
 36 **A\*01:01, HLA-A\*02:01, HLA-A\*24:02.** The orange color bars show the number of peptides  
 37 that increased the affinity to 50 nM and less; the blue color bars indicate the number of  
 38 peptides with a decreased affinity to more than 50 nM.

39 Supplementary figures  
 40



41  
 42 **Figure S1. The number of unique viral peptides interacting with the sets of HLA molecules**  
 43 **corresponding to the genotypes (affinity of no more than 50 nM). (A) Comparison of HLA-**  
 44 **A\*01:01 vs non HLA-A\*01:01 carriers. (B) Comparison of Wave 1 vs Wave 3 groups.**  
 45